Senescence-Associated Exosome Release from Human Prostate Cancer Cells

Brian D. Lehmann, Matthew S. Paine, Adam M. Brooks, James A. McCubrey, Randall H. Renegar, Rong Wang, and David M. Terrian

Abstract

Males of advanced age represent a rapidly growing population at risk for prostate cancer. In the contemporary setting of earlier detection, a majority of prostate carcinomas are still clinically localized and often treated using radiation therapy. Our recent studies have shown that premature cellular senescence, rather than apoptosis, accounts for most of the clonogenic death induced by clinically relevant doses of irradiation in prostate cancer cells. We show here that this treatment-induced senescence was associated with a significantly increased release of exosome-like microvesicles. In premature senescence, this novel secretory phenotype was dependent on the activation of p53. In addition, the release of exosome-like microvesicles also increased during proliferative senescence in normal human diploid fibroblasts. These data support the hypothesis that senescence, initiated either by telomere attrition (e.g., aging) or DNA damage (e.g., radiotherapy), may induce a p53-dependent increase in the biogenesis of exosome-like vesicles. Ultrastructural analysis and RNA interference–mediated knockdown of Tsg101 provided significant evidence that the additional exosomes released by prematurely senescent prostate cancer cells were principally derived from multivesicular endosomes. Moreover, these exosomes were enriched in B7-H3 protein, a recently identified diagnostic marker for prostate cancer, and an abundance of what has recently been termed “exosomal shuttle RNA.” Our findings are consistent with the proposal that exosomes can transfer cargos, with both immunoregulatory potential and genetic information, between cells through a novel mechanism that may be recruited to increase exosome release during accelerated and replicative cellular senescence.

Introduction

Advanced age is the dominant risk factor for developing carcinoma of the prostate. The incidence of prostate cancer increases dramatically in men beyond 50 years of age and reaches a frequency of one-in-seven between ages 60 and 79 years (1). Once a prostatic intraepithelial neoplasia has been initiated, a host of age-related alterations have the potential to influence the evolution and growth of malignant lesions; including chronic oxidative stress and inflammation, genomic instability, a loss of immune surveillance and telomere attrition. Telomere attrition limits the reproductive life span of normal human cells by inducing a permanent cell cycle arrest that is termed replicative senescence (2). Although replicative senescence is generally considered a natural tumor suppressor mechanism, owing to its antiproliferative effects, there is now evidence that senescent prostate fibroblasts populating aged tissue may secrete soluble growth factors capable of altering the host microenvironment (3). Understanding the relationships between biological aging, this “senescent secretory phenotype,” and age-related diseases such as prostate cancer represents an emerging area of active research.

Although no longer dividing, senescent fibroblasts remain metabolically active and secrete high levels of epithelial growth factors and matrix metalloproteinases (4–8). Thus, an accumulation of senescent fibroblasts can alter the surrounding microenvironment; the so-called “reactive stroma” associated with some carcinomas, and promote the growth and tumor progression of initiated human prostate epithelial cells (9). The factors secreted by senescent cells vary depending on cell type and the vast majority of studies to date have analyzed this senescent secretory phenotype using normal fibroblasts that have reached replicative exhaustion as a cell model (4–9). These studies have convincingly shown that the p53, p21WAF1/Cip1 (p21), p16INK4a (p16), and pRb tumor suppressors are important senescence regulators (10). The functional collaboration between the p16/pRb and p53/p21 pathways responsible for initiating a permanent growth arrest have been described in detail (11, 12), yet we still understand little about the age-related mechanisms involved in initiating or maintaining the senescent secretory phenotype.

External beam radiation has long been one of the major curative treatment options for patients with clinically localized prostate cancer. We have recently presented evidence that the in vitro effectiveness of this treatment modality may be principally attributed to its ability to induce a p53-dependent terminal growth arrest, termed accelerated or “premature senescence,” rather than a direct cell kill (13). There is no direct evidence that the clinical use of irradiation induces premature senescence in prostate tumor cells in vivo. However, there is evidence that chemotherapeutics and irradiation selectively induce premature senescence within the malignant foci of breast cancer specimens (14).

Much recent attention has been focused on the task of identifying soluble factors secreted by senescent fibroblasts and tumor cells and in characterizing their paracrine activities (3–8, 15). It is important to note, however, that in addition to soluble paracrine factors, many tumor cells also release microvesicles that have been termed “exosomes” (16). Exosomes are small, cup-shaped, vesicles of ~100 nm diameter that are initially formed within the endosomal compartment and are secreted when a multivesicular endosome (MVE) fuses with the plasma membrane (17, 18). Interestingly, the abundance of exosomes released generally correlates positively with advanced stages of cancer...
progression (16). Moreover, there is recent evidence that the irradiation-induced activation of p53 has the potential to increase exosome release from nonquiescent human lung cancer cells (19).

In the present study, we sought to determine whether a relationship exists between the irradiation-induced activation of p53, premature cellular senescence and alterations in exosome biogenesis in human prostate cancer cells. We compared presenescent (i.e., mock-irradiated) and senescent (irradiated) prostate cancer cells for alterations in the senescence-associated secretion of exosome-like particles. This analysis identified a novel and previously unrecognized connection between the induction of p53-dependent senescence and the release of endosome-derived exosomes in human prostate cancer cells. Moreover, our analysis of replicative senescence in normal human fibroblasts provided preliminary evidence of a more general functional relationship that may be intrinsic to this mode of clonogenic death. Importantly, the results of our biochemical analyses also support the concept that senescence-associated exosomes can transfer cargos, with both immunoregulatory potential and genetic information, between cells through a novel mechanism that may be recruited to increase exosome release during cellular senescence.

Materials and Methods

Cell Culture
LNCaP, 22Rv1, and DU145 cells were acquired from the American Type Culture Collection (ATCC CRL-1740, CRL-2505, and HTB-81, respectively). LNCaP and 22Rv1 cultures were maintained in RPMI 1640 medium containing 2 mmol/L of L-glutamine, 10 mmol/L of HEPES, 1 mmol/L of sodium pyruvate, 4.5 g/L of glucose, and 1.5 g/L of sodium bicarbonate, supplemented with 10% fetal bovine serum (FBS), 100 units/mL of penicillin and 100 mg/mL of streptomycin. The effects of p53 inactivation on irradiation-induced cellular senescence and exosome release were examined by infecting LNCaP and 22Rv1 cells with a retroviral vector encoding dominant negative (DN) p53 as described previously (13).

DU145 cells were cultured in MEM with 2 mmol/L of L-glutamine and Earle's balanced salt solution adjusted to contain 1.5 g/L of sodium bicarbonate, 0.1 mmol/L of nonessential amino acids, 0.1 mmol/L of sodium pyruvate, supplemented with 10% FBS and 100 units/mL of penicillin and 100 mg/mL of streptomycin. Normal human dermal fibroblasts (NHDF) were obtained from Dr. Warren Knudson (Department of Anatomy and Cell Biology, East Carolina University, Greenville, NC) and were grown as an adherent culture with MEM containing 2 mmol/L of L-glutamine and Earle's balanced salt solution adjusted to contain 1.5 g/L of sodium bicarbonate, 0.1 mmol/L of nonessential amino acids, 0.1 mmol/L of sodium pyruvate, supplemented with 10% FBS and 100 units/mL of penicillin and 100 mg/mL of streptomycin.

Senescence Induction
Accelerated senescence. Subconfluent cultures of human prostate cancer cells (LNCaP, 22Rv1, and DU145) were routinely seeded in triplicate and allowed to proliferate to ~70% confluence prior to mock-irradiation (0 Gy) or exposure to an irradiation dose of 4 Gy, using a GammaCell 40 (Atomic Energy of Canada Limited) Cs137 source. After treatment, the cells were left to recover for 4 days in complete medium. At this time postirradiation, a majority of LNCaP and 22Rv1, but not DU145, cells test positive for various phenotypic markers of cellular senescence (13) and could be used for comparisons of exosome release from presenescent (mock-irradiated) versus prematurely senescent (irradiated) cells.

Replicative senescence. To establish cells at replicative senescence, NHDF cells were cultured until cell doubling time exceeded 12 days (>10 cell doublings). At this time, the cells were considered to have reached replicative exhaustion. Induction of senescence was routinely verified by measuring the increased senescence-associated β-galactosidase (SA-β-Gal) activity, as described previously (13).

Exosome Purification and Analysis
Exosomes were isolated from medium conditioned by LNCaP, 22Rv1, and DU145 cells using the differential centrifugation protocol of Thery and colleagues (20), with the following modifications. Subconfluent cultures were washed twice in PBS and incubated for 48 h in serum-free medium. In our studies of irradiation-induced senescence, this period of conditioning was initiated 4 days after a single exposure to either 0 or 4 Gy. This conditioned medium was decanted, centrifuged at 500 × g for 10 min to sediment cells and at 14,000 × g for 15 min to eliminate cell debris. Exosomes were sedimented by ultracentrifugation at 100,000 × g for 70 min and the resultant pellets were washed once in PBS. The washed pellets were examined by electron microscopy (see below) and examined for their protein or lipid content using SDS-PAGE and Daichi silver staining, immunoblotting, or stained using Vybrant DiI (Molecular Probes), a fluorescent carbocyanine lipid analogue that uniformly stains biological membranes (21). For lipid staining, equal aliquots of the final exosome suspensions were incubated for 20 min at 37°C in the presence of 5 μmol/L of DiI and excess dye was removed by washing in PBS. The fluorescent intensity (Ex590, Em609) of these DiI-stained membrane fractions were measured using a Synergy HT microplate reader (Bio-Tek) and used for comparisons of vesicle secretion. All values were corrected for differences in the total number of viable cells left on the plate after the 48-h conditioning period, and then measured using the trypan blue exclusion assay.

Electron Microscopy
Exosome preparations from LNCaP and 22Rv1 cells were mixed with equal quantities of freshly prepared 4% paraformaldehyde and 5 μL of the sample was loaded onto carbon-coated formvar grids. After incubation in a moist atmosphere for 20 min, the samples were washed thrice in PBS and then fixed for 5 min in 1% glutaraldehyde. After three washes, the exosome samples were stained for 10 min with saturated aqueous uranyl. Exosomes were examined with a JEOL 1200EX electron microscope at 60 kV.

Western Blot Analysis
Immunoblots were performed as described previously (13). Antibodies purchased from R&D Systems were raised against human B7-H3. Anti-Tsg101 antibody (C-2) was purchased from Santa Cruz Biotechnology. Anti-β-actin antibody (Ab-1) was purchased from Calbiochem. Where specified, the relative intensity of immunospecific bands were analyzed with a Molecular Dynamics densitometer and ImageQuant software (GE Healthcare).

RNA Interference
22Rv1 cells were transfected with oligomer-Lipofectamine 2000 complexes using 100 nmol/L of human Tsg101 SMARTpool small interfering RNAs (siRNA; NM_006292) or a nontargeting siRNA control, according to the manufacturer’s protocol (Dharmacon, Inc.). Briefly, 3 days after cells had either been mock-irradiated or exposed to a 4 Gy dose, the cultures were washed with PBS and incubated for 24 h in serum-free medium. 22Rv1 cells were then incubated for 24 h in the presence of 100 nmol/L of siRNA-Lipofectamine complexes before the medium was replaced with serum- and siRNA-free medium. After 72 h, the conditioned medium was removed for exosome purification and cell lysates were prepared using the corresponding adherent cells.

Total RNA Extraction and Analysis
Exosome fractions were resuspended in RNase-free water, briefly sonicated, and total nucleic acid was extracted using TRIzol reagent, according to the manufacturer’s protocol (Invitrogen Corp.). RNA precipitates were resuspended in RNase-free PBS and divided into three equal aliquots. Control samples were incubated for 10 min at 37°C, whereas the remaining two were incubated, under identical conditions, in the presence of either 0.4 μg/μL of RNase or 0.083 units/μL of DNase. These samples were separated on 2% agarose gels and stained with ethidium bromide.
Analysis of Clonogenic Survival and Cell Fate

Assays of clonogenic survival after a single exposure to 2 Gy (SF₂), apoptosis (i.e., TdT-mediated dUTP nick end labeling, flow cytometric analysis of DNA content, and acridine orange/ethidium bromide staining), and cellular senescence (SA-β-Gal and carboxyfluorescein diacetate succinimidyl ester flow cytometry) were performed as previously described (13).

Data Analysis

Values shown are representative of triplicate determinations in two or more experiments, unless otherwise specified, and treatment effects were evaluated using a two-sided Student’s t test. Errors are SE of averaged results and P < 0.05 values were taken as a significant difference between means.

Results and Discussion

The three primary responses mediated by p53 in response to irradiation-induced DNA damage are cell cycle arrest, apoptosis, or cellular senescence. Collectively, data from our previous study strongly supported the idea that, within 4 days, a single exposure to radiation could lead to the emergence of a prematurely senescent subpopulation of prostate cancer cells (13). Other studies suggest that senescent cells such as these have the potential to influence a tumor microenvironment through the secretion of soluble protumorigenic and antitumorigenic factors (3, 6, 8, 12, 15). However, the assortment of factors secreted seems to be cell type– and tissue-specific (12, 15). Senescent prostate fibroblasts have recently been shown to secrete soluble growth factors (3). Proteomic profiling of the soluble factors secreted by a variety of senescent cell types is currently a subject of intense investigation. However, we have found that the particulate material secreted by senescent prostate cancer cells may be equally informative.

Evidence of an endosomal origin for irradiation-induced exosome release. To establish a subpopulation of prematurely senescent cells, LNCaP and 22Rv1 cells were irradiated and allowed to accumulate over a period of 4 days before the medium was replenished with fresh serum-free medium and conditioned for 2 days, as previously described (13). Microvesicles secreted by these presenescent cells were isolated from the conditioned medium and the final fractions were examined by electron microscopy or stained using the lipid probe Vybrant DiI (21). Electron micrographs revealed that 22Rv1 cells released cup-shaped, rounded vesicles with a size of ~80 to 150 nm (Fig. 1A), similar to exosomes released by LNCaP prostate cancer cells (data not shown; ref. 18) and other cell types (18–20). Of note was the absence of any visual evidence of contamination by membrane fragments in our preparations of exosome-like particles. Additional evidence that microvesicles released by 22Rv1 cells were of endosomal origin is presented below (Fig. 1B).

Vybrant DiI was used as a sensitive fluorescent probe for measuring changes in the bulk level of microvesicles released by cells. The fluorescent intensity of these DiI-stained fractions were corrected for differences in the total number of viable cells left on each plate after the 48-hour conditioning period. The results of this assay provided evidence that the irradiation-induced senescence of 22Rv1 cells (13) was associated with an approximate 3-fold increase in the bulk level of microvesicles released by their unirradiated controls (Fig. 1C). These data indicate that irradiation therapy has the potential to induce a senescent phenotype associated with increased production and release of exosome-like particles into the microenvironment of neighboring cells that could potentially influence tumor progression.

We next used RNA interference to determine the cellular origin of the studied exosome-like particles. Two modes of exosome biogenesis have been described, immediate or delayed (22). The immediate mode of exosome biogenesis generates secreted vesicles that bud outward (i.e., away from the cytoplasm) from certain domains of the plasma membrane. This mode of exosome formation has been reported to be independent of class E vacuolar protein sorting function and MVEs (22). In contrast, the delayed mode of exosome biogenesis begins with outward vesicle budding at the limiting membrane of endosomes, generating MVEs. We targeted Tsg101 because this ubiquitin-binding protein is required for MVE vesicle formation (23) and a Tsg101 siRNA sequence had recently been shown to be effective in selectively decreasing the level of Tsg101 protein in PC3 prostate cancer cells (23). Four days after an exposure to mock, or 4 Gy irradiation, 22Rv1 cells were transfected with 100 nmol/L of Tsg101 siRNA and then incubated for an additional 3 days in antibiotic-free and serum-free medium.

![Figure 1](https://cancerres.aacrjournals.org/content/68/19/7866/F1.large.jpg)

**Figure 1.** Ultrastructural and functional analysis of exosomes released from 22Rv1 prostate cancer cells. A, electron micrograph of 22Rv1 exosome-like particles. The image shows small cup-shaped vesicles of ~60 to 150 nm in diameter, which are representative of the exosome-like vesicles released by both 22Rv1 and LNCaP cells. Exosome fractions were isolated from serum-free medium conditioned by 22Rv1 cells for 48 h, beginning 4 d after irradiation (4 Gy). Bar, 200 nm. B, Western blot analysis of Tsg101 down-regulation in irradiated 22Rv1 cells. A mock transfection (Control) or transfection with a Tsg101 mismatch RNA (mmRNA) or Tsg101 siRNA (both 100 nmol/L) on day 3 after irradiation (4 Gy) was followed by harvesting of cell lysates on day 6. C, fluorescence assay of particulate membranes collected from medium conditioned on days 5 to 6 postirradiation. 22Rv1 cells were exposed to 0 or 4 Gy; incubated 4 d and transfected with Tsg101 mismatch RNA, siRNA, or untreated. After an additional 2 d, particulate fractions were isolated and stained. All values were then corrected for differences in viable cells left on the plate after 0 or 4 Gy. Columns, mean derived from two independent experiments done in triplicate; bars, SE; *, P < 0.01, Student’s t test.
A 3-day exposure to Tsg101 siRNA resulted in an ~70% down-regulation at the protein level (ImageQuant TL; Fig. 1B) and ~55% reduction in basal exosome release in subconfluent cultures of proliferating 22Rv1 cells (i.e., unirradiated controls; Fig. 1C). Neither the mismatch RNA nor untreated control samples showed a significant change in Tsg101 protein levels or exosome release. Identical treatments with Tsg101 siRNA resulted in a 65% reduction in the extent to which irradiation-induced senescence was associated with an up-regulation of exosome release, when compared with the mismatch RNA and untreated controls (Fig. 1C, filled columns). Thus, electron microscopy and specific siRNA knockdown of Tsg101 provided significant evidence in favor of an endosomal/MVE origin for the vesicles under study.

**p53-dependent and senescence-associated exosome release.**

A novel role for p53 in the control of intracellular protein trafficking has been proposed (8) and, more recently, it was shown that irradiation-induced activation of p53 can lead to significantly increased levels of exosome biogenesis and secretion by cultured human lung cancer cells (24). Moreover, there is evidence that the intrinsic MVE-exosomal transport pathway may be up-regulated in both ovarian cancer cells and erythroleukemic cells treated with the anticancer drug doxorubicin, which also activates a p53-dependent DNA damage response pathway (25, 26). Because prostate cancer cells also secrete exosome-like vesicles (18), we examined human prostate cancer cells for a potential functional relationship between irradiation-induced p53 activation, cellular senescence, and exosome secretion.

First, we analyzed conditioned medium from cultures of mock-treated (0 Gy) or irradiated (4 Gy) 22Rv1 cells for the presence of membrane vesicles at various times after treatment. Using SA β-Gal as an indicator of cellular senescence, the percentage of prematurely senescent 22Rv1 cells did not significantly increase within the 3 days following irradiation but had climbed to ~50% within 5 days postirradiation (Fig. 2A). Concurrent with this sharp increase in the relative number of prematurely senescent cells was an increase in the release of exosome-like vesicles from irradiated 22Rv1 cells (Fig. 2B). Beginning on the day specified, cultures were washed with PBS and incubated an additional 2 days in fresh serum-free medium to eliminate the possibility of any contamination by FBS-derived exosomes. The bulk level of particulate membrane which accumulated between 2 and 4 days after irradiation did not differ between mock controls and irradiated cultures. However, when the onset of conditioning was not initiated until the onset of premature cellular senescence (4 days postirradiation; ref. 13) there was a significantly greater amount of membrane vesicles accumulated in the medium conditioned by irradiated versus unirradiated 22Rv1 cells (Fig. 2B). This discrepancy remained evident, and grew, during the subsequent 4 days postirradiation (Fig. 2B).

Second, to determine whether this secretory pattern was restricted to senescent populations of prostate cancer cells, we compared the bulk levels of particulate membranes which accumulated between 4 and 6 days after cultured prostate cancer cells were exposed to either 0 or 4 Gy. A significant percentage of LNCaP and 22Rv1 cells become senescent within 4 days after irradiation (13), and there was a significant increase in the release of membrane vesicles associated with the irradiation-induced initiation of this cellular senescence (Fig. 2C and D). In contrast, DU145 cells neither display several of the phenotypic characteristics of a senescent cell nor increase in vesicle release following a single exposure to radiation (Fig. 2C and D; ref. 13). Further evidence of a link between irradiation-induced p53 activation, premature senescence, and increased exosome release is presented...
in Fig. 3. Compared with their parental counterparts, fewer LNCaP and 22Rv1 cells transfected with a DN p53 mutant stained positive for SAβ-Gal 4 days after irradiation and the observed differences in the release of exosome-like vesicles were diminished; each of these differences were statistically significant (Fig. 3). These data are consistent with the hypothesis that an increased biogenesis and/or release of exosome-like vesicles may comprise an important and previously unrecognized feature of premature cellular senescence.

Third, we tested the hypothesis that an increase in p53 activity would both enhance irradiation-induced cellular senescence and exosome secretion. To do this, we used nutlin-3, a small molecule antagonist of MDM2 that disrupts a negative feedback loop involving p53 ubiquitination (27). Nutlin-3 effectively primes the p53 pathway to respond to irradiation-induced DNA damage by increasing basal levels of p53 protein (Fig. 4A). Data shown in Fig. 4B summarize our recent findings (13) that MDM2 inhibition significantly decreases the clonogenic survival of LNCaP cells following a single exposure to the clinically relevant dose of 2 Gy (surviving fraction after 2 Gy = SF2; Fig. 4B). Moreover, this radiosensitizing effect of nutlin-3 has previously been shown to be blocked by the expression of a DN p53 mutant (13) and could be entirely attributed to an increased induction of p53-dependent cellular senescence, rather than an increased percentage of apoptotic and necrotic cells (Fig. 4B). Finally, the introduction of nutlin-3 30 minutes prior to irradiation (4 Gy) and throughout the following 4 days resulted in a more than 2-fold increase in the release of exosome-like vesicles (Fig. 4C). This is the first investigation of the concept that p53 activity, premature senescence, and exosome biogenesis may be functionally coupled by intracellular signals and events that remain uncertain and represent important gaps in our current understanding of the secretory pattern of senescent cells.

To determine whether this secretory pattern was restricted to prematurely senescent populations of prostate cancer cells, we examined cultures of NHDF. NHDF cells have a finite life span in vitro and generally remain proliferative for less than 12 population doublings. When the bulk levels of particulate membranes released by proliferating and nonproliferating (i.e., senescent) cultures were
compared, we observed a >15-fold increase in the release of exosome-like particles from NHDF cells that had naturally reached a state of replicative senescence (Fig. 5). These data provide strong support for the hypothesis that senescence, initiated either by telomere attrition (e.g., aging) or DNA damage (e.g., radiotherapy), may induce a p53-dependent increase in the biogenesis of exosome-like vesicles. This previously unrecognized feature of cellular senescence may hold important clues about the basic biology of both aging and the premature senescence of cancer cells.

Preliminary analysis of exosome cargo secreted by prematurely senescent prostate cancer cells. To determine whether irradiation-induced senescence was associated with qualitative, as well as quantitative, changes in MVE cargo sorting, we performed a SDS-PAGE analysis of the proteins associated with exosomal fractions collected from unirradiated and irradiated LNCaP and 22Rv1 cells. These assays showed that proteins detected in these gels were not derived from serum contamination of the exosome fractions (Fig. 6, left, lane 4) and confirmed that irradiation-induced senescence did not alter the overall profile of exosome proteins released (Fig. 6A). Moreover, comparisons of the proteins present in 22Rv1-derived whole cell lysates, exosome fractions, and soluble proteins indicated that exosomes were enriched in various subclasses of cellular proteins (Fig. 6, right, e.g., bands of ~13, 16, 30, 47, 58, 65, and 90 kDa). We have established that B7-H3 (CD276) represents one of the proteins enriched in the exosomes released by 22Rv1 cells (Fig. 6B). However, the presence of this protein has not been detected in exosomes released by LNCaP cells, possibly due to the relatively slow rate of exosome release from this cell line (Fig. 6A). In 22Rv1 cells, irradiation-induced senescence was associated with an increased release of B7-H3–positive exosomes that were free of contamination by cytosolic or mitochondrial proteins (e.g., ERK1/2 or cytochrome C; Fig. 6C); thus, providing independent confirmation of results obtained using DiI as a lipid probe to detect changes in exosome release. This is a novel and important finding, as B7-H3 is a member of the B7 family of proteins that are capable of modulating CD4 T-cell responses and antitumoral immunity (28–31). It was recently reported that increased B7-H3 expression provides an extremely reliable marker of prognosis for differentiating indolent from aggressive prostate cancers (32). The precise role of B7-H3 in prostate cancer and immunosurveillance has yet to be established. However, as a prognostic biomarker for aggressive cases of prostate cancer, B7-H3 has shown promise in immunohistochemical analyses of tissue sections (33). Because B7-H3 protein can be detected in the exosomes released by senescent 22Rv1 cells, it is possible that meaningful changes in the levels of circulating B7-H3–positive exosomes in the blood may provide a noninvasive way to survey the efficacy of radiotherapy for patients with prostate cancer.

Finally, we have extended the recent discovery by Valadi and colleagues (34) that exosomes contain small RNA. In this important study, the authors showed that exosomes released from mouse and human mast cells contain an abundance of small mRNAs and microRNAs (34). In addition, it was established that RNA from mouse mast cells was transferable to recipient human mast cells and can be translated after entering the recipient cell. In our preliminary analysis, we have found that prematurely senescent (irradiation-induced) 22Rv1 cells also release exosomes containing substantial amounts of small RNAs (Fig. 6D; <100 bp). To confirm that the nucleotides detected by agarose gel electrophoresis were RNA, exosome extracts were treated with either RNase or DNase in solution. The results showed minimal degradation by DNase, whereas added RNase degraded exosome RNA and revealed the presence of a single DNA band of >1,000 bp (Fig. 6D). The studies described here present the challenges of addressing the basic questions of whether the RNA cargo contained in MVE-derived exosomes are generally capable of mediating cell-cell communication, as in the case of human mast cells (34), and to investigate the mechanisms of “exosomal shuttle RNA” uptake by neighboring cells.

Clinically relevant doses of irradiation induce a premature state of cellular senescence that accounts for most of the clonogenic death observed in cultures of human prostate cancer cells retaining a functional p53 DNA damage-response pathway (13). We show here for the first time that this treatment-induced cell cycle arrest was associated with a senescence-associated increase in exosome release. In accelerated senescence, this novel secretory phenotype was dependent on the activation of p53. However, the release of exosome-like microvesicles also increased during proliferative senescence in normal human fibroblasts. This suggests that senescence, initiated either by telomere attrition (e.g., aging) or DNA damage (e.g., radiotherapy), may induce a p53-dependent increase in the biogenesis of exosome-like vesicles. Ultrastructural analysis and RNA interference–mediated knockdown of Tsg101 provided significant evidence that the additional exosomes released by prematurely senescent prostate cancer cells were principally derived from MVEs. Moreover, these exosomes were enriched in B7-H3 protein, a recently identified diagnostic marker for prostate cancer and an abundance of exosomal shuttle RNA. Many details regarding the mechanisms that control exosome biogenesis and their potential role in intercellular communication remain obscure. Our findings are consistent with the proposal that exosomes can transfer cargos, with both immunoregulatory potential and genetic information, between cells through a novel mechanism that may be recruited to increase exosome release during treatment-induced and replicative cellular senescence.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
Acknowledgments

Received 12/7/2007; revised 7/14/2008; accepted 7/16/2008.

Grant support: NIH grant R01CA098195 (J.A. McCubrey) and the Brody Brother's Foundation Endowment no. 997729 (D.M. Terrian and J.A. McCubrey).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Warren Knudson for the NHDF cells and members of the Anatomy and Cell Biology Workshop Series for their many helpful suggestions.

Figure 6. Secretion patterns of human prostate cancer cells. A, silver staining analysis of the exosome fractions released, 4 to 6 d after exposure to either 0 or 4 Gy, by 22Rv1 cells. Left, electrophoresis was performed on 8% to 16% Tris-glycine gels; lane 4 is a negative control loaded with unconditioned serum-free medium (Uncond. SFM). Right, comparison of the silver-stained protein profiles for 22Rv1 total cell lysates, exosome fractions, and exosome-free medium (Soluble fraction) conditioned 4 to 6 d after irradiation (4 Gy). Electrophoresis was performed on 4% to 20% gels. B, Western blot analysis of B7-H3 protein in a whole cell lysate and exosome fraction isolated from medium conditioned 48 h by irradiated 22Rv1 cells. C, Western blot analysis of B7-H3 protein in exosome fractions and an absence of contamination by either cytochrome C or ERK1/2. Exosomes were isolated 4 d after the exposure of 22Rv1 cells to either 0 or 4 Gy; total cell lysates were prepared from remaining adherent cells. Final exosome pellets were resuspended in equal volumes of lysis buffer and 20% of the total volumes for each sample were loaded. The position of molecular weight markers (in kDa; left). D, large amounts of small RNA (<100 bp) were detected in 22Rv1-derived exosomes on a 2% agarose gel stained by ethidium bromide; treatments with either RNase or DNase confirmed the presence of both DNA and RNA.

References


Cancer Res 2008; 68: (19). October 1, 2008 7870 www.aacrjournals.org

Downloaded from cancerres.aacrjournals.org on July 22, 2017. © 2008 American Association for Cancer Research.


Senescence-Associated Exosome Release from Human Prostate Cancer Cells

Brian D. Lehmann, Matthew S. Paine, Adam M. Brooks, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/19/7864

Cited articles
This article cites 34 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/19/7864.full#ref-list-1

Citing articles
This article has been cited by 9 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/68/19/7864.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.